# Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)

> **NCT03942120** · — · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 685 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT03942120
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-08
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 685 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03942120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03942120, "Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03942120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*